🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Feasibility Study of a Chatbot AI-Driven Preliminary Screening System for Hereditary Cancer Syndromes

Recruitingn/aAges 21 Years - 99 YearsAllNational Cancer Centre, Singapore
NCT07901543 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to assess the feasibility of implementing an AI-based hereditary cancer preliminary screening system that has already been developed. This validation cohort will consist of healthy individuals and cancer patients, including those already suspected to be at risk of hereditary conditions.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Singapore citizen or permanent resident * Individuals from the general public or patients at NCCS * Adults (aged 21 or older) who are capable of giving informed consent Exclusion Criteria: * Under the age of 21 years old * Incapable of giving informed consent
💊

What it tests

  • Hereditary cancer preliminary screening chatbot
📍

Where

1 site
National Cancer Center Singapore
Singapore, Singapore
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy